SCHEMBL4833715

SCHEMBL4833715

CON(C)C(=O)C(O[Si](C)(C)C(C)(C)C)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
FAAH O00519 1/20 0.36
KDM4E B2RXH2 1/20 0.36
AOC3 Q16853 1/20 0.36
KMT2A Q03164 3/20 0.35
JAK3 P52333 1/20 0.34
BTK Q06187 1/20 0.34
ALDH1A1 P00352 2/20 0.34
MEN1 O00255 2/20 0.34
CYP3A4 P08684 1/20 0.34
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34
GLS O94925 4/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7725831 0.88 FAAH (0.38) FAAHKDM4EALDH1A1
SCHEMBL4833441 0.86 FAAH (0.37) FAAHAOC3KMT2AALDH1A1
SCHEMBL4839775 0.84 TEAD1 (0.37) FAAH
SCHEMBL18568034 0.83 KDM4E (0.32) FAAHKDM4EJAK3BTKALDH1A1
SCHEMBL15049933 0.82 ADRB2 (0.38) L3MBTL1KDM4EAOC3KMT2AALDH1A1
SCHEMBL29529432 0.82 ADRB2 (0.38) L3MBTL1KDM4EAOC3KMT2AALDH1A1
SCHEMBL15049932 0.82 ADRB2 (0.38) L3MBTL1KDM4EAOC3KMT2AALDH1A1
SCHEMBL7567010 0.81 ATM (0.42) ATML3MBTL1KDM4EKMT2AALDH1A1
SCHEMBL3232420 0.81 ATM (0.42) ATML3MBTL1KDM4EKMT2AALDH1A1
SCHEMBL8405171 0.81 ATM (0.42) ATML3MBTL1KDM4EKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7320995-B2 Benzimidazoles and benzothiazoles as inhibitors of map kinase ELI LILLY AND COMPANY (US) 2008-01-22 US disclosed
EP-1554272-B1 BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE LILLY CO ELI (US) 2006-10-25 EP disclosed
US-20050272791-A1 Benzimidazoles and benzothiazoles as inhibitors of map kinase EIL LILLY AND COMPANY (US) 2005-12-08 US disclosed
EP-1554272-A1 BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE ELI LILLY AND COMPANY (US) 2005-07-20 EP disclosed
WO-2004014900-A1 BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE ELI LILLY AND COMPANY (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272791-A1 Benzimidazoles and benzothiazoles as inhibitors of map kinase MAP3K8, MAPK8, MAPK1 ATM 824/4885L3MBTL1 589/4885FAAH 4425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.